Dolutegravir-associated hyperglycaemia in patients with HIV

Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients

RATIONALE The integrase inhibitor dolutegravir is now recommended as first-line treatment for HIV. A single case of myocarditis after treatment with dolutegravir was reported in the FLAMINGO trial. We present here 2 cases of severe myocarditis that occurred shortly after the initiation of dolutegravir treatment. PATIENTS CONCERNS The first case is a 45-year-old female who developed severe con...

Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load.

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

BACKGROUND Little is known about the applicability of dual treatments based on integrase inhibitors. We explored the combination of lamivudine + dolutegravir as an option when switching from standard cART in virologically suppressed patients. METHODS In this prospective cohort we enrolled patients previously switched to 3TC + DTG who were 18 years or older, with no previous resistance mutatio...

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

AIM Dolutegravir is the newest integrase inhibitor approved for HIV treatment and has demonstrated potent antiviral activity in patient populations with a broad range of treatment experience. This analysis aimed to characterize the population pharmacokinetics of dolutegravir in treatment-naive patients and to evaluate the influence of patient covariates. METHODS A population pharmacokinetic m...

evaluation of fat atrophy in patients with dermis fat graft of orbit by ct-scan

چکیده ندارد.